AMAG Pharmaceuticals EBITDA margin
What is the EBITDA margin of AMAG Pharmaceuticals?
The EBITDA margin of AMAG Pharmaceuticals, Inc. is -33.61%
What is the definition of EBITDA margin?
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
EBITDA margin of companies in the Health Care sector on NASDAQ compared to AMAG Pharmaceuticals
What does AMAG Pharmaceuticals do?
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. Its products include Intrarosa, Vyleesi, Makena, CBR, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.
Companies with ebitda margin similar to AMAG Pharmaceuticals
- DraftKings has EBITDA margin of -33.83%
- Sarepta Therapeutics Inc has EBITDA margin of -33.83%
- Awilco Drilling Plc has EBITDA margin of -33.82%
- Cannabis Strategic Ventures has EBITDA margin of -33.75%
- Kaixin Auto has EBITDA margin of -33.71%
- XPON Technologies Ltd has EBITDA margin of -33.69%
- AMAG Pharmaceuticals has EBITDA margin of -33.61%
- Nutraplus India has EBITDA margin of -33.60%
- Tuya has EBITDA margin of -33.58%
- Mirum Pharmaceuticals Inc has EBITDA margin of -33.57%
- Glory Mark Hi-Tech () has EBITDA margin of -33.54%
- Emperor Entertainment Hotel has EBITDA margin of -33.54%
- Avicanna has EBITDA margin of -33.48%